small molecule

LEQSELVI

DEURUXOLITINIB PHOSPHATE

Loss of exclusivityOctober 2044latest FDA-listed patent expiry

CompanySUN PHARMACEUTICAL INDUSTRIES INC

Drug detail

Brand name	LEQSELVI
Active ingredient	DEURUXOLITINIB PHOSPHATE
Strength	EQ 8MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12364699	October 2044	use U-3976
12247034	May 2044	substance, product
12285432	August 2042	use U-3976
11919907	May 2041	product
10561659	May 2037	use U-3976
12076323	May 2037	use U-3976

Regulatory exclusivity

Code	Expires
NCE	July 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from SUN PHARMACEUTICAL INDUSTRIES INC